abrdn Life Sciences Investors Fund maintains a buy rating, offering a compelling 11.6% yield and trading at a 9.58% NAV discount. HQL’s income-focused strategy relies on net realized gains, supporting ...
Tekla Life Sciences Investors is a closed-ended equity fund that primarily invests in the life sciences sector, with a heavy focus on biotech and pharmaceuticals. The fund's dividend history has been ...
$HQL insiders have traded $HQL stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales. Here’s a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results